Drug Trial Radar · NCT05543174
A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)
Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Jan 16, 2023
Primary completion
Oct 25, 2023
Study completion Jul 25, 2025
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future. The participants will be treated with TAK-625 for up to the end of study (about 34 months). Participants will visit their study clinic 9 times from the start of study. After 9 times visits, participants will visit their study clinic every 12 weeks up to the end of study.
Conditions
- Alagille Syndrome (ALGS)
Interventions
TAK-625Drug
TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22Time frame: From Week 18 to Week 22
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Kyoto University Hospital
Kyoto, Japan
Saitama Prefectural Children's Medical Center
Saitama, Japan
University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan
Yokohamashi Tobu Hospital
Yokohama, Kanagawa, Japan
Miyagi Children's Hospital
Sendai, Miyagi, Japan
Kindai University Nara Hospital
Ikoma, Nara, Japan
Osaka University Hospital
Suita, Osaka, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.